Neural Blockade Monitor

Rethinking Anesthesia: Introducing the Neural Blockade Monitor

Anesthesiology has advanced dramatically over the past century—but at least one critical gap has remained: clinicians still lack a real-time, objective way to measure the effectiveness of local anesthetics during surgery. Until now.

BIOPAC is proud to introduce the Neural Blockade Monitor (NBM)—a groundbreaking medical device technology that brings objective, non-invasive, real-time monitoring to the world of regional anesthesia. This innovation bridges decades of progress in anesthetic agents and techniques with the fundamental need for data-driven decision-making in clinical care.

Local anesthetics, which block transmission of nerve signals from the source of pain to the brain, have revolutionized peri-operative pain management. But despite their widespread use, there has never been a reliable way to determine how well a nerve block is working—until the patient either feels pain or doesn’t. The NBM changes that by enabling clinicians to see, in real time, how effectively a nerve block is working during OBGYN, Pediatric, Orthopedic, and other surgeries requiring a nerve block.

BIOPAC is developing this technology in collaboration with BLOCKsynop, Inc. and the Johns Hopkins University Applied Physics Laboratory (APL), the NBM offers:

• Real-time monitoring of nerve block location and density leading to Improved patient safety 

• Quantitative reporting of block effectiveness

• Targeted and informed dosing to reduce anesthetic toxicity

• Patient-specific precision in peri-operative regional anesthesia management

Through this partnership, BIOPAC has licensed the NBM technology and is working to bring it to market as a clinically validated medical device. We are transforming the way pain is managed—objectively, safely, and in real time.